DBV Technologies S.A. (NASDAQ:DBVT) Receives $6.50 Average PT from Analysts


Share on StockTwits

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have earned a consensus recommendation of “Hold” from the thirteen brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, six have given a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $6.50.

Several research firms have commented on DBVT. Zacks Investment Research lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Thursday, January 7th. BidaskClub raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Thursday, January 7th. Finally, Societe Generale raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research note on Monday, November 2nd.

Several hedge funds have recently bought and sold shares of the company. Boxer Capital LLC boosted its stake in shares of DBV Technologies by 7.1% during the 3rd quarter. Boxer Capital LLC now owns 7,534,598 shares of the company’s stock worth $13,035,000 after acquiring an additional 500,000 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its position in shares of DBV Technologies by 4.5% during the 2nd quarter. ArrowMark Colorado Holdings LLC now owns 6,009,182 shares of the company’s stock worth $26,380,000 after purchasing an additional 258,257 shares during the last quarter. First Midwest Bank Trust Division raised its position in shares of DBV Technologies by 849.7% during the 3rd quarter. First Midwest Bank Trust Division now owns 732,293 shares of the company’s stock worth $1,267,000 after purchasing an additional 655,189 shares during the last quarter. OLD Mission Capital LLC raised its position in shares of DBV Technologies by 647.4% during the 3rd quarter. OLD Mission Capital LLC now owns 137,880 shares of the company’s stock worth $239,000 after purchasing an additional 119,432 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of DBV Technologies by 917.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 113,537 shares of the company’s stock worth $194,000 after purchasing an additional 102,375 shares during the last quarter. 43.25% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:DBVT traded up $0.03 during mid-day trading on Wednesday, hitting $3.73. The company’s stock had a trading volume of 312,817 shares, compared to its average volume of 954,928. DBV Technologies has a 1 year low of $1.35 and a 1 year high of $13.02. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.28 and a quick ratio of 4.22. The stock has a market cap of $409.77 million, a price-to-earnings ratio of -1.60 and a beta of 2.87. The business’s fifty day moving average is $2.85 and its two-hundred day moving average is $2.64.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.

Featured Story: FTSE 100 Index

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.